期刊文献+

Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NFκB 被引量:3

Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NFκB
下载PDF
导出
摘要 AIM- To investigate the reduction of cell viability in human hepatocellular carcinoma (HCC) cell lines induced by inhibition of nuclear factor kB (NFkB). METIIOI)S: HLE, SKHep1, and HepG2 were incubated and E3330 was used to compare the stimulation of some chemotherapeutic drugs with that of TNF family, Fas ligand, TNF(x and TNF-related apoptosis-inducing ligand (TRAIL) at the point of the reduction of cell viability by inhibiting NFkB. RESULTS: E3330 decreased NFKB levels in HLE cells stimulated by TNF and TRAIL. The cytotoxicity of the combination of TRAIL, TNFa, Fas ligand, and E3330 increased synergistically in a dose-dependent manner compared to either E3330 alone in all HCC cell lines by MTT assay. However, the combination of some chemotherapeutic drugs and E3330 did not decrease the cell viability. CONCLUSION: Inhibition of NFd3 sensitizes human HCC cell lines to TNF-mediated apoptosis including TRAIL, and TRAIL-based tumor therapy might be a powerful potential therapeutic tool in the treatment of human HCC. AIM: To investigate the reduction of cell viability in human hepatocellular carcinoma (HCC) cell lines induced by inhibition of nuclear factor κB (NFκB). METHODS: HLE, SKHep1, and HepG2 were incubated and E3330 was used to compare the stimulation of some chemotherapeutic drugs with that of TNF family, Fas ligand, TNFα and TNF-related apoptosis-inducing ligand (TRAIL) at the point of the reduction of cell viability by inhibiting NFκB. RESULTS: E3330 decreased NFκB levels in HLE cells stimulated by TNF and TRAIL. The cytotoxicity of the combination of TRAIL, TNFα, Fas ligand, and E3330 increased synergistically in a dose-dependent manner compared to either E3330 alone in all HCC cell lines by MTT assay. However, the combination of some chemotherapeutic drugs and E3330 did not decrease the cell viability. CONCLUSION: Inhibition of NFκB sensitizes human HCC cell lines to TNF-mediated apoptosis including TRAIL, and TRAIL-based tumor therapy might be a powerful potential therapeutic tool in the treatment of human HCC.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第40期6258-6261,共4页 世界胃肠病学杂志(英文版)
关键词 E3330 NFkB inhibitor Cytotoxicity TRAIL TNFA Fas ligand DOXORUBICIN Camptotecin 肿瘤坏死因子 肝细胞癌 E3330 肿瘤细胞
  • 相关文献

参考文献11

  • 1K. Miyamoto,J. Nagakawa,I. Hishinuma,K. Hirota,M. Yasuda,T. Yamanaka,K. Katayama,I. Yamatsu.Suppressive effects of E3330, a novel quinone derivative, on tumor necrosis factor-α generation from monocytes and macrophages[J].Agents and Actions (-).1992(3-4)
  • 2Schulze-Osthoff K,Ferrari D,Los M,Wesselborg S,Peter ME.Apoptosis signaling by death receptors[].European Journal of Biochemistry.1998
  • 3Thompson CB.Apoptosis in the pathogenesis and treatment of disease[].Science.1995
  • 4Grilli M,Chiu JJ,Lenardo MJ.NF-kappa B and Rel: participants in a multiform transcriptional regulatory system[].International Review of Cytology.1993
  • 5Baeuerle PA,Henkel T.Function and activation of NF-kappa B in the immune system[].Annual Review of Immunology.1994
  • 6Nagata S.Apoptosis by death factor[].Cell.1997
  • 7Pan G,Ni J,Wei YF,Yu C,Gentz R,Dixit VM.An antagonist decoy receptor and a death domain-containing receptor for TRAIL[].Science.1997
  • 8Schneider P,Bodmer JL,Thome M,Hofmann K,Holler N,Tschopp J.Characterization of two receptors for TRAIL[].FEBS Letters.1997
  • 9Shiraki K,Tsuji N,Shioda T,Isselbacher KJ,Takahashi H.Expression of Fas ligand in liver metastases of human colonic adenocarcinomas[].Proceedings of the National Academy of Sciences of the United States of America.1997
  • 10Kuhnel F,Zender L,Paul Y,Tietze MK,Trautwein C,Manns M,Kubicka S.NFkappaB mediates apoptosis through tran-scriptional activation of Fas (CD95) in adenoviral hepatitis[].Journal of Biological Chemistry.2000

同被引文献20

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部